Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
PaperCitations, authors & open-access status
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 324 citations, 2021 year and hybrid oa status.
324
Citations
2021
Year
hybrid
OA Status